**Legends to supplementary figures and tables**

Supplementary Table S1. Clinicopathological characteristics of the PORTEC-1 and -2 trial populations: comparison of cases included in the current analysis and those excluded for lack of material (n=164), non-endometrioid histology (n=30) or failed molecular analysis (n=86).

Supplementary Table S2. Hotspot mutation frequency according to the four molecular subgroups in early-stage endometrial cancer (n=834).

Supplementary Table S3. Clinicopathological characteristics, additional mutations and protein expression alterations in tumours with multiple classifying alterations.

Supplementary Table S4. Multivariable analysis on the prognostic role of the clinicopathological characteristics, molecular subgroups, and potential other classifiers in all cases of early-stage endometrial cancer (n=834) and in the subset of EC without substantial LVSI, >10% L1CAM, p53 and *POLE* mutation (n=620).

Supplementary Table S5. Univariable analysis of clinicopathological characteristics, molecular subgroups, and potential other classifiers in low-risk early-stage endometrial cancer (n=242).